Noramco is moving forward with a broad offering of clinical- to commercial-scale cannabinoid APIs for branded and generic pharmaceuticals. The comprehensive offering includes everything a drug manufacturer requires to advance cannabinoid-based APIs to finished dosage forms.
Research and logistics professionals responsible for Noramco’s European operations now operate out of a new facility in Neuhausen, Switzerland. Approximately 30 employees work at the state-of-the-art center…
Researchers at Noramco study analytical methods to detect and determine the presence of potentially genotoxic impurities (PGIs) in pharmaceutical products.
Why is Noramco leveraging expertise in APIs to provide solutions to stability, bioavailability, and purity challenges?
Meet us at CPhI Worldwide for more information about “one-stop API development and manufacturing.”